Earnings ·
Reports Q3 GAAP net income of $100.7M driven by non-cash warrant gain; adjusted loss widens to $5.6M
NERVMinerva Neurosciences, Inc.
Minerva Neurosciences reported a GAAP net income of $100.7 million, or $1.94 per basic share, for the quarter ended September 30, 2026, compared to a net loss of $2.7 million in the prior-year period. The result was driven by a $109.6 million non-cash gain on the change in fair value of warrant liability issued during an October 2025 private placement. Excluding this gain and stock-based compensation, adjusted net loss widened to $5.6 million from $2.5 million, as R&D expenses rose to $5.2 million due to ongoing Phase 3 trial costs for roluperidone. The company confirmed its confirmatory Phase 3 trial (C19) is on track with topline efficacy data expected in the second half of 2027. Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.